Semuloparin

Drug Profile

Semuloparin

Alternative Names: AVE5026; Mulsevo; Octaparin; Octaparine; Semuloparin sodium; Visamerin

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Anticoagulants; Antithrombotics; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Submission Withdrawal Thromboembolism

Most Recent Events

  • 20 Jul 2012 Discontinued - Phase-II for Thromboembolism (prevention; children and adolescents with a central venous line) in Hungary (SC)
  • 20 Jul 2012 Discontinued - Phase-II for Thromboembolism (prevention; children and adolescents with a central venous line) in Singapore (SC)
  • 09 Jul 2012 Regulatory submission withdrawn for Thromboembolism (prevention in patients receiving chemotherapy) in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top